{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-036543","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.288017+00:00","generated_at":"2026-05-17T22:49:03.639316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"United Therapeutics Reports Record Q2 2025 Revenue of $798.6M, Authorizes $1B Buyback","bullets":["Record total revenue of $798.6 million, up 12% year-over-year, driven by Tyvaso DPI growth of 22% to $315 million.","Board authorized up to $1 billion in share repurchases through March 31, 2026.","Phase 3 TETON 2 study of Nebulized Tyvaso in IPF complete; data expected September 2025.","Orenitram posted record quarterly revenue of $123.9 million, up 16% year-over-year.","Net income of $309.5 million, or $6.86 per basic share, up 11%."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-036543","json":"https://secwatch.observer/filing/0001628280-25-036543.json","markdown":"https://secwatch.observer/filing/0001628280-25-036543.md","text":"https://secwatch.observer/filing/0001628280-25-036543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000162828025036543/0001628280-25-036543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000162828025036543/uthr-20250730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T22:49:03.639316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}